ITM Isotope Technologies Munich and Radiopharm (RADX) Theranostics announced the signing of a supply agreement that will provide Radiopharm with ITM’s medical radioisotope, non-carrier-added Lutetium-177, to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm’s development pipeline. Under the terms of the agreement, Radiopharm will use ITM’s n.c.a. 177Lu across its clinical pipeline, including in key programs such as RAD 204, RAD 202, and RV01, for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM’s n.c.a. 177Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue